Abstract
BMS309403 is a biphenyl azole inhibitor against fatty acid binding protein 4 (FABP4) and regarded as a lead compound for effective treatment of obesity related cardio-metabolic diseases. Here we discovered an off-target activity of BMS309403 in that it stimulates glucose uptake in C2C12 myotubes in a temporal and dose dependent manner via activation of AMP-activated protein kinase (AMPK) signaling pathway but independent of FABPs. Further analysis indicated that BMS309403 activates AMPK through increasing the ratio of intracellular AMP:ATP while decreasing mitochondrial membrane potential. These findings provide mechanistic insights on the action of BMS309403. © 2012 Lin et al.
Cite
CITATION STYLE
Lin, W., Huang, X., Zhang, L., Chen, D., Wang, D., Peng, Q., … Wu, D. (2012). BMS309403 Stimulates Glucose Uptake in Myotubes through Activation of AMP-Activated Protein Kinase. PLoS ONE, 7(8). https://doi.org/10.1371/journal.pone.0044570
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.